Clinical Trials Browser

INDUSTRY × soluble LAG-3 protein, human × 90 days × Clear all

NCT03625323 2026-04-22

TACTI-002

Phase 2 Completed

187 enrolled 13 charts

Squamous Cell Carcinoma of Head and Neck

NCT06726265 2026-03-18

Study of Eftilagimod Alfa (Efti) in Combination With Pembrolizumab and Chemotherapy Versus Placebo in Combination With Pembrolizumab and Chemotherapy in Participants With Metastatic Non-Small Cell Lung Cancer (NSCLC) (TACTI-004)

Phase 3 Active not recruiting

Carcinoma, Non-Small-Cell Lung